dr fillinger
TRANSCRIPT
![Page 1: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/1.jpg)
Mark Fillinger MD for the PYTHAGORAS Investigators
Two-year Pythagoras US Pivotal Trial Results for the Aorfix device in
Highly Angulated Aortic Necks
D00979a
![Page 2: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/2.jpg)
Disclosure
Speaker name: Mark Fillinger
.................................................................................
x I have the following potential conflicts of interest to report:
x Consulting (WL Gore, Endologix, Cook)
D00979a
![Page 3: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/3.jpg)
Aorfix™ Device Designed and tested to treat
highly angulated aortic necks
Highly flexible, soft, conformable device
Polyester fabric, Nitinol rings
4 pairs of hooks proximally
8 mm long primary seal zone
Commonly placed in a trans-renal position
D00979a
![Page 4: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/4.jpg)
U.S. Pythagoras Clinical Trial: First EVAR Trial in aortic neck angles 60-90 degrees EVAR Arms
‘Roll-in’ Group: 67 EVAR pts, neck angle <60°
Primary Study Group: 151 EVAR pts, neck angles 60-90°(and higher)
The US trial enrolled 218 patients on intent-to-treat
Control Arms SVS Registry meta-analysis of control patients from US
EVAR clinical trials (n=323) Concurrently enrolled Open Surgical controls (n=76) for
neck angulation and other variables not in SVS registry
D00979a
![Page 5: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/5.jpg)
Demographics, Comorbidities, Anatomy
• EVAR and open control patients had similar AAA sac diameter (5.8 cm in each group, p=ns), but the high-angle group differed from open controls with regard to factors previously shown to adversely affect outcomes:
Age (EVAR 76 ± 7, vs 69 ± 7 years, p<0.001),
Female (EVAR 29%, high angle 35%, vs open 20%, p<0.02)
Neck angle (EVAR all 71 ± 22, EVAR high angle 83 ± 15, vs Open 48 ± 23 degrees, p<0.001) ; EVAR 69% > 60°, Open 27% > 60° (p<.05)
First trial with more female pts in the test group
First trial with more severe neck angles in the test groupD00979a
![Page 6: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/6.jpg)
Interaction between neck angle, gender
0
5
10
15
20
25
30
>0 >10 >20 >30 >40 >50 >60 >70 >80 >90
Num
ber o
f Pat
ient
s
Neck Angle (Degrees)
Angle Distribution By Gender
M Count F Count
D00979a
![Page 7: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/7.jpg)
Gender Distribution, EVAR Trials
D00979a
![Page 8: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/8.jpg)
Effect of Neck Angle on Seal Zone
Centerline: 15 mm long “neck”
Inner Curve: 8 mm long seal zone
In highly angulated aortic necks, the central lumen line (centerline) is not a good indicator of the actual seal zone.
D00979a
![Page 9: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/9.jpg)
Mean Neck Lengths (± 1SD) in IDE Studies
0
5
10
15
20
25
30
35
40
45
50
Talent Endurant Ovation Aorfix All Aorfix <60 Aorfix ≥60
-1SD
+1SD
Mean
D00979a
![Page 10: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/10.jpg)
Results: 30 day + Hospital Aortic endografts were successfully implanted in
210/218 cases on intent-to-treat (all 8 were access-related, device not attempted in 4/8).
Mortality was 1.8% for the entire cohort (4/218), 2.0% for the 60-110° angle group (3/153), and 2.8% for the open controls (9/323, p=ns)
30-day outcomes favored the test group for procedure duration, EBL, transfusion, and hospital length of stay (all p<0.05).
D00979a
![Page 11: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/11.jpg)
Freedom from SVS Major Adverse Events (MAEs): Aorfix EVAR Superior to Open Controls
* P<0.0001 for all Aorfix groups vs Open controls
**
* **
*
D00979a
![Page 12: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/12.jpg)
EVAR-specific Results
%
Aorfix™All
N=218
Aorfix™60-110°
N=151
Aorfix™<60°
N=67
SVS control group
N=323Freedom from SVS-defined MAE (30 d) 85% 82% 93% 56%
Freedom from SVS-defined MAE (1 yr) 80% 76% 88% 55%
Mortality (30 d) 1.8% 2.0% 1.5% 2.8%
Sac shrinkage (5mm 1 yr) 42% 44% 37% -
Sac expansion (5mm 1 yr) 1.2% 1.8% 0% -
Type I/III leak (1yr) 1.6% 2.0% 0% -
Migration (1yr) 1.4% 1.7% 0% -
Wire Fracture (1yr)(pre-Nitinol change) 6.2% 6.1% 6.4% -
D00979a
![Page 13: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/13.jpg)
EVAR-specific Results – 2 years
%
Aorfix™All
N=218
Aorfix™60-110°
N=151
Aorfix™<60°
N=67
SVS control group
N=323Freedom from SVS-defined MAE (2 yr) 73% 70% 79% 55% (1 yr)
Mortality (2 yr) 11% 14% 5% NA
Sac shrinkage (5mm 2yr) 54% 54% 55% -
Sac expansion (5mm 2yr) 5% 5% 4% -
Type I/III leak (2 yr) 0% 0% 0% -
Migration (2 yr) 3% 4% 2% -
Wire Fracture (2 yr)(pre-Nitinol change) 14% 16% 10% -
D00979a
![Page 14: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/14.jpg)
Freedom from All-cause Mortality: Intent to Treat Basis
Test subjects older: EVAR 76 ±8, vs 69 ±7 years, p=0.001
D00979a
![Page 15: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/15.jpg)
Freedom from Aneurysm-Related Mortality: Intent to Treat Basis
Test subjects older: EVAR 76 ±8, vs 69 ±7 years, p=0.001
D00979a
![Page 16: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/16.jpg)
Freedom from Secondary Interventions: Intent to Treat Basis
D00979a
![Page 17: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/17.jpg)
DHMC Case #2: Device straightens, short available seal zone remains sealed
Pre-implant 1 Month post-implant 1 Year post-implant
D00979a
![Page 18: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/18.jpg)
Norfolk case: Adapts at neck and iliac limbs
6 month Post Op
Images Courtesy of Dr Marc Glickman and Dr Jean Panneton, Sentara Heart Hospital, Norfolk, VA
Limbs in sac adapt to dramatic AAA sac shrinkage
D00979a
![Page 19: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/19.jpg)
Limitations and Tips Read the IFU, learn the device deployment,
start with normal anatomy
Access: make sure its adequate, do open conduits if you aren’t good at endoconduits
Put the device at the renal arteries: that is where the neck is stable
Watch the renals in angulated necks: use proper c-arm gantry angles based on CTA
D00979a
![Page 20: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/20.jpg)
Summary The Pythagoras Clinical Trial of the Aorfix endograft is the
first EVAR Pivotal trial focusing on highly-angulated aortic necks (60-90 degrees).
Despite predictors of worse short and long-term outcomes, MAEs are superior to open repair, and EVAR-specific outcomes are similar to trials with much less severe anatomy.
Based on Pythagoras results, Aorfix was FDA-approved for 0-90° neck angles, and remains the only on-label alternative to open repair for patients with highly angulated aortic necks.
D00979a
![Page 21: Dr fillinger](https://reader037.vdocuments.us/reader037/viewer/2022110122/55a75c5e1a28ab97148b45ba/html5/thumbnails/21.jpg)
Pythagoras Investigators
D00979a